Verve Therapeutics
Verve Therapeutics Raises $213M in Series C
Quick Facts
Verve Therapeutics Raises $213M in Series C
Verve Therapeutics has successfully raised $213M in a Series C at a $1B valuation led by Foresite Capital, GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital.
Company Overview
Verve Therapeutics is a Biotech company headquartered in 26 Landsdowne Street, Cambridge, MA 02139, founded in 2018 with 200+ employees.
Gene editing for heart disease
Fundraising Details
- Amount Raised: $213M
- Round Type: Series C
- Valuation: $1B
- Date: 2024-10-26
- Investors: Foresite Capital, GV, F-Prime Capital, ARCH Venture Partners, Biomatics Capital
About Verve Therapeutics
Gene editing for heart disease The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: 26 Landsdowne Street, Cambridge, MA 02139
- Founded: 2018
- Team Size: 200+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Verve Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Verve Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $1B valuation marks an important milestone for Verve Therapeutics, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Verve Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-10-26. For more information about Verve Therapeutics, visit their headquarters at 26 Landsdowne Street, Cambridge, MA 02139.
About the Author
Related Company Reports
Harvey AI Raises $160 million in Series F
Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.
7AI Raises $130 million in Series A
7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.
TRIANA Biomedicines Raises $120 million in Series B
TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.